OakChart

Lakewood-Amedex Biotherapeutics Inc

LABTHealthcare·Biotechnology·USA·Nano·NASD·Nov 12 • 11:18 AM ET

0.3749-0.0201 (-5.09%)
2026-11-12 17:18 CET
Market cap
0.94 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-7.35 USD m
Free cash flow, TTM
-3.49 USD m
EPS diluted, TTM
-10.34
P/E
-
Compare

Price

LABT against its 20 and 50-day averages
2050beatearnings
Patternshover a marker to name it
EPS mean, own scalesmoothed
RS 0EPS -1.33Price-1.33-0.810.0010.0020.0030.00376.9M753.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26LABTclose 0.3820-day 0.3750-day 1.030.38

99.6% under the 52-week high of 98.20 on 23 Apr 2026. 52-week low 0.17 on 2 Nov 2026. Last 15 sessions, 468.0% high to low. This session is unfinished.

Volume 0.15× normal · the line is the 50-bar volume average

Profile

LABT
52-week range, 0% of the way up
0.1798.20

Lakewood-Amedex Biotherapeutics, Inc. engages in the development of novel antimicrobial therapies. Its anti-infective products targeted certain viral diseases like avian influenza, Epstein Barr Virus (EBV), and hepatitis B and C. The company was founded by Roderic Dale on July 11, 2006 and is headquartered in Bradenton, FL.

Employees5
IPOApr 23, 2026
ATR, 14d0.13
Rel volume0.15
Short float9.68%
Insider own33.38%
Inst own6.49%

Snapshot

6 groups

Valuation

Index-
Market Cap0.89M
Enterprise Value-3.59M
Income-7.35M
Sales0.00M
Book/sh2.00
Cash/sh1.92
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees5
IPOApr 23, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.19
P/C0.19
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio7.70
Current Ratio7.70
Debt/Eq0.02
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-10.34
EPS next Y-
EPS next Q-1.33
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y17.02% -
Sales past 3/5Y- -
EPS Y/Y TTM-140.44%
Sales Y/Y TTM-
EPS Q/Q-769.45%
Sales Q/Q-
EarningsSep 02
EPS/Sales Surpr.0.00% -

Ownership

Insider Own33.38%
Insider Trans0.00%
Inst Own6.49%
Inst Trans67.96%
ROA-225.45%
ROE-402.84%
ROIC-169.64%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA201.32%
SMA50-63.44%
SMA200-94.48%
Trades-

Technical

Shs Outstand2.17M
Shs Float1.58M
Short Float9.68%
Short Ratio0.01
Short Interest0.15M
52W High98.20 -99.62%
52W Low0.17 122.23%
Volatility54.69% 25.61%
ATR (14)0.13
RSI (14)38.44
Beta-
Rel Volume0.15
Avg Volume14.84M
Volume678,503

Performance

Perf Week-30.65%
Perf Month-40.65%
Perf Quarter-83.48%
Perf Half Y-98.09%
Perf YTD-99.53%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price7.50
Prev Close0.40
Price0.37
Change %-5.09%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Oct 28, 2026InitiatedHH.C. WainwrightBuy$3+700.2%

Peers

Mkt cap
TickerCompanyMkt cap
ACXPAcurx Pharmaceuticals Inc5.67M
MTNBMatinas Biopharma Holdings Inc0.91M
SPROSpero Therapeutics Inc59.38M
VBIOValion Bio Inc1.11M
ABVCABVC BioPharma Inc26.16M
AARDAardvark Therapeutics Inc34.16M
COAGHemab Therapeutics Holdings Inc1.82B
ABEOAbeona Therapeutics Inc129.15M
ABOSAcumen Pharmaceuticals Inc16.25M
ACETAdicet Bio Inc27.99M

News

latest 14 of 44
  • Lakewood-Amedex Biotherapeutics Announces Completion of Series C Convertible Preferred Stock Redemption (InvestorsHub) +182.45%
  • Lakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026 (PR Newswire) -19.31%
  • Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin Compounds (PR Newswire)
  • Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences (PR Newswire)
  • Lakewood-Amedex Reports Positive Nu-3 MIC Data Against Diabetic Foot Ulcer Clinical Isolates (InvestorsHub) -31.14%
  • Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers (PR Newswire)
  • Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers (PR Newswire)
  • Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3 (PR Newswire)
  • Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers (PR Newswire) +6.99%
  • Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference (PR Newswire) +15.96%
  • Lakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company (NewMediaWire) +7.51% +6.99%
  • Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PR Newswire) +83.33%
  • Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel (PR Newswire)
  • Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance (PR Newswire) -12.77%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-09-02-2.660-2.660-1.7390.000.001
2026Q12026-06-03-1.320--2.0000.00--
2026Q3---1.330--0.002
2026Q4---1.100--0.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-272000.000.000.00
2026Q3S2026-09-021000.000.000.00
2026Q3S2026-06-231000.000.000.00
2026Q3R2026-09-02101-0.81-0.81-0.81
2026Q3R2026-08-26101-0.81-0.81-0.81
2026Q3R2026-06-23100-0.56-0.56-0.56
2026Q3E2026-10-27201-1.33-1.85-0.81
2026Q3E2026-09-02101-0.81-0.81-0.81
2026Q3E2026-08-26101-0.81-0.81-0.81
2026Q3E2026-06-23100-0.56-0.56-0.56
2026Q2S2026-06-231000.000.000.00
2026Q2R2026-08-26101-2.66-2.66-2.66
2026Q2R2026-06-23100-0.65-0.65-0.65
2026Q2E2026-08-26101-2.66-2.66-2.66

Estimate history

EPS, annual-12.2-7-8.4-10.3389
Period202320242025TTM
EPS, quarterly-0.3-2.8-1.2-0.1-0.2-2.7-3.9-2-1.739
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000
Period202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.6830.6940.72.169
Period202320242025MRQ
Shares, quarterly4.1190.6940.6944.114.110.70.70.72.169
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY
Total Revenue0.000.000.000.00
Cost of Goods Sold Incl. D&A0.120.120.120.12
Gross Profit-0.12-0.12-0.12-0.12
Selling, General and Administrative Excl. Other7.153.653.918.52
Research and Development0.320.100.313.48
Other Operating Expense0.000.000.000.00
Operating Income-7.27-3.77-4.03-8.64
Interest Expense0.120.100.010.01
Unusual Expense0.000.001.040.00
Net Income Before Taxes-7.35-3.85-4.86-8.28
Income Taxes0.000.000.000.00
Consolidated Net Income-7.35-3.85-4.86-8.28
Net Income From Continuing Operations-7.35-3.85-4.86-8.28
Net Income-7.35-3.85-4.86-8.28
EPS (Recurring)-3.39-5.53-5.97-12.16
EPS (Basic, Before Extraordinaries)-10.34-8.40-7.00-12.20
EPS (Diluted)-10.34-8.40-7.00-12.20
EBITDA-7.15-3.65-3.91-8.52
Non-Operating Income (Expense)0.050.030.220.36
Other After Tax Adjustments0.000.000.000.00
Stock Option Compensation Expense1.361.350.270.61
Shares Outstanding2.170.700.690.68
Market Capitalization0.940.94--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.030.030.030.030.030.030.030.03
Gross Profit-0.03-0.03-0.03-0.03-0.03-0.03-0.03-0.03
Selling, General and Administrative Excl. Other3.760.860.681.850.610.510.830.88
Research and Development0.240.020.020.040.010.030.030.10
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.79-0.89-0.71-1.88-0.64-0.54-0.86-0.91
Interest Expense0.010.040.040.040.020.00-0.00
Unusual Expense0.000.000.000.000.000.000.001.04
Net Income Before Taxes-3.77-0.92-0.74-1.91-0.66-0.54-0.85-1.94
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-3.77-0.92-0.74-1.91-0.66-0.54-0.85-1.94
Net Income From Continuing Operations-3.77-0.92-0.74-1.91-0.66-0.54-0.85-1.94
Net Income-3.77-0.92-0.74-1.91-0.66-0.54-0.85-1.94
EPS (Recurring)-1.74-1.32--2.74-0.16-0.13--1.74
EPS (Basic, Before Extraordinaries)-1.74-2.00-3.90-2.70-0.20-0.10-1.20-2.80
EPS (Diluted)-1.74-2.00-3.90-2.70-0.20-0.10-1.20-2.80
EBITDA-3.76-0.86-0.68-1.85-0.61-0.51-0.83-0.88
Non-Operating Income (Expense)0.030.000.000.010.010.000.010.02
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.060.050.051.200.050.050.060.07
Shares Outstanding2.170.700.700.704.114.110.690.69
Market Capitalization0.946.09------

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY
Cash & Short Term Investments0.240.686.39
Short Term Receivables0.000.000.00
Inventories0.000.000.00
Other Current Assets0.070.090.09
Total Current Assets0.310.776.48
Net Property, Plant & Equipment0.170.290.40
Total Investments and Advances0.000.000.00
Other Assets0.010.010.01
Total Assets0.481.076.89
Short Term Debt Incl. Current Port. of LT Debt1.620.110.31
Accounts Payable0.000.000.00
Other Current Liabilities0.790.391.76
Total Current Liabilities2.410.502.06
Long Term Debt0.040.160.27
Provision for Risks Charges0.000.000.00
Other Liabilities0.000.000.00
Total Liabilities2.450.662.34
Non-Equity Reserves0.000.000.00
Preferred Stock - Carrying Value0.000.000.00
Common Equity-1.970.414.56
Total Shareholders Equity-1.960.414.56
Accumulated Minority Interest0.000.000.00
Total Equity-1.960.414.56
Total Liabilities & Stockholders Equity0.481.076.89
Book Value Per Share-2.810.596.67
Tangible Book Value Per Share-2.810.596.67
Full-Time Employees5--
Price to Book Ratio0.20--
Return on Assets-495.77-121.93-
Return on Equity--195.47-
Return on Invested Capital--851.90-171.43
Quick Ratio0.131.553.14
Current Ratio0.131.553.14

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY
Net Income-7.35-3.85-4.86-8.28
Depreciation0.120.120.120.12
Other Funds (Non Cash)3.791.350.200.53
Funds from Operations-3.43-2.37-4.53-7.63
Extraordinary Item0.000.000.000.00
Changes in Working Capital-0.050.43-1.190.81
Cash from Operating Activities-3.49-1.94-5.72-6.82
Capital Expenditures0.000.00-0.000.00
Net Assets From Acquisitions0.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.00
Purchase or Sale of Investments-2.000.003.93-3.78
Purchase of Investments-2.000.00-4.33-11.13
Sale Or Maturity of Investments0.000.008.267.34
Other Uses0.000.000.000.00
Other Sources0.000.000.000.00
Cash from Investing Activities-2.000.003.92-3.78
Cash Dividends Paid0.000.000.000.00
Change in Capital Stock6.800.00-0.050.00
Repurchase of Common Pref Stock0.000.00-0.050.00
Sale of Common Pref Stock6.800.000.000.00
Proceedsfrom Stock Options6.800.000.000.00
Issuance or Reduction of Debt, Net0.001.500.000.00
Change in Long Term Debt0.000.000.000.00
Issuance of Long Term Debt0.000.000.000.00
Reduction of Long Term Debt0.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.00
Other Financing Activities Uses0.000.000.000.00
Cash from Financing Activities6.801.50-0.050.00
Net Change in Cash1.32-0.44-1.85-10.60
Free Cash Flow-3.49-1.94-5.73-6.82
Deferred Taxes & Investment Tax Credit-0.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments4.580.010.240.661.270.48
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.260.040.070.120.050.07
Total Current Assets4.850.050.310.781.320.55
Net Property, Plant & Equipment0.110.140.170.200.230.26
Total Investments and Advances0.000.000.000.000.000.00
Other Assets0.010.010.010.010.010.01
Total Assets4.960.200.480.991.560.82
Short Term Debt Incl. Current Port. of LT Debt0.101.751.621.621.620.31
Accounts Payable0.000.000.000.000.000.00
Other Current Liabilities0.531.280.790.560.520.45
Total Current Liabilities0.633.032.412.182.140.76
Long Term Debt0.000.010.040.070.100.13
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities0.633.042.452.252.240.89
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value5E-050.000.000.000.000.00
Common Equity4.33-2.84-1.97-1.27-0.69-0.08
Total Shareholders Equity4.33-2.84-1.96-1.27-0.68-0.08
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity4.33-2.84-1.96-1.27-0.68-0.08
Total Liabilities & Stockholders Equity4.960.200.480.991.560.82
Book Value Per Share2.00-4.07-2.81-1.81-0.17-0.02
Tangible Book Value Per Share2.00-4.07-2.81-1.81-0.17-0.02
Full-Time Employees--55--
Price to Book Ratio0.20-0.86----
Return on Assets-225.45-834.41-495.77---
Return on Equity-402.84-----
Return on Invested Capital-87.09-----979.23
Quick Ratio7.700.020.130.360.620.72
Current Ratio7.700.020.130.360.620.72

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-3.77-0.92-0.74-1.91-0.66-0.54
Depreciation0.030.030.030.030.030.03
Other Funds (Non Cash)2.500.050.051.200.050.05
Funds from Operations-1.25-0.85-0.67-0.67-0.58-0.46
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.860.500.250.060.070.05
Cash from Operating Activities-2.10-0.35-0.42-0.61-0.51-0.40
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-2.000.000.000.000.000.00
Purchase of Investments-2.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-2.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)---0.00--
Change in Capital Stock6.800.000.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock6.800.000.000.000.000.00
Proceedsfrom Stock Options6.800.000.000.000.000.00
Issuance or Reduction of Debt, Net-0.120.120.000.001.300.20
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities6.680.120.000.001.300.20
Net Change in Cash2.57-0.22-0.42-0.610.79-0.20
Free Cash Flow-2.10-0.35-0.42-0.61-0.51-0.40

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.68%0.2M1.6M2.34M
2026-10-155.70%0.1M1.6M2.45M
2026-09-308.27%0.1M1.6M2.39M
2026-09-153.35%0.1M1.6M1.86M
2026-08-313.89%0.1M1.6M1.67M
2026-08-143.56%0.1M1.6M1.53M
2026-07-319.77%0.1M1.3M1.59M
2026-07-152.50%0.0M1.0M304.42K
2026-06-302.16%0.0M1.8M286.01K
2026-06-15-0.0M-281.28K
2026-05-291.28%0.0M0.3M384.75K
2026-05-152.44%0.0M0.6M330.83K
2026-04-302.07%0.0M0.4M111.38K

Option chain

expiry 2026-11-12
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-108-KCurrent report2026-11-04SEC
2026-09-298-KCurrent report2026-09-22SEC
2026-09-24EFFECTEffectiveness filing by commission orderSEC
2026-09-18S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-08-24DRSSEC
2026-08-17424B3SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-14SCHEDULE 13GSEC
2026-08-10DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-08-10DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-22SEC
2026-08-06SCHEDULE 13GSEC
2026-07-30PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-07-30SEC
2026-07-158-KCurrent report2026-07-15SEC
2026-06-23SCHEDULE 13GSEC
2026-06-22424B3SEC
2026-06-22424B3SEC
2026-06-178-KCurrent report2026-06-15SEC
2026-05-26424B3SEC
2026-05-26424B3SEC
2026-05-2210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-14424B4SEC
2026-05-13EFFECTEffectiveness filing by commission orderSEC
2026-05-12CORRESPSEC
2026-05-08UPLOADUpload SubmissionSEC
2026-05-064Statement of changes in beneficial ownership of securities2026-04-24SEC
2026-05-063Initial statement of beneficial ownership of securities2026-04-24SEC
2026-05-013Initial statement of beneficial ownership of securities2026-04-17SEC
2026-05-013Initial statement of beneficial ownership of securities2026-04-17SEC
2026-05-013Initial statement of beneficial ownership of securities2026-04-17SEC
2026-05-013Initial statement of beneficial ownership of securities2026-04-17SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Marex Group Ltd2.75%
HRT FINANCIAL LP2.56%
GEODE CAPITAL MANAGEMENT, LLC1.89%
CITIGROUP INC0.45%
UBS Group AG0.19%
Tower Research Capital LLC0.04%
OSAIC HOLDINGS, INC.0.01%
Blue Trust, Inc.0.00%

Funds

Fund% owned
Fidelity Nasdaq Composite Index Fund1.83%
Fidelity Extended Market Index Fund0.06%

OakChart. LABT. Cached 15 minutes.

Some panels did not load: insider.